Vectus Biosystems Limited (AU:VBS)
ASX:VBS
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)97.35K
Market Cap
AU$8.02M
Enterprise ValueAU$8.15M
Total Cash (Recent Filing)AU$330.50K
Total Debt (Recent Filing)AU$467.10K
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding53,433,330
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently high gross margins indicate the core therapies or products have strong unit economics and pricing power. Over 2–6 months this supports sustainable contribution margins as topline recovers, enabling R&D investment or partner deals to leverage margin tailwinds despite operating losses.
Modest Absolute DebtModest absolute debt reduces near-term refinancing pressure versus highly leveraged peers. With limited interest burden, the company has greater flexibility to prioritize clinical programs or licensing efforts, lowering immediate solvency risk even if equity and cash metrics remain weak.
IP-driven Biotech ModelAn IP/licensing revenue model supports durable, non-linear cash inflows via partnerships, milestones and royalties. Over months this model can de-risk cash runway if a licensing deal is struck, and it aligns incentives with larger pharma for late‑stage development and commercialization.
Bears Say
Sharply Declining RevenueA near 46% revenue decline is a structural red flag for commercial traction and contract continuity. Over the medium term it reduces internal funding capacity, increases reliance on external financing, and weakens bargaining power with partners, imperiling program continuity.
Persistent Cash BurnRepeated negative operating and free cash flow shows losses are translating to real cash outflows. This persistent burn demands external funding within months, risks dilution or covenant pressure, and can disrupt multi‑year clinical programs absent clear near-term financing.
Negative Shareholders' EquityNegative equity materially weakens the balance sheet, distorts leverage metrics, and reduces financial flexibility. In the medium term this raises refinancing and counterparty risks, may limit access to traditional credit, and increases the probability of dilutive capital raises.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.04 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$8.02M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Aug 28, 2026 which is in 151 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Feb 20, 2026. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 53,433,330 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.677%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.75%
12-Months-Change
Fundamentals
Return on Equity
265.12%
Trailing 12-Months
Asset Growth
-62.59%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.